Midwest University Healthtech Showcase

MATTER is teaming up with research universities across the Midwest to showcase their top healthcare technologies. Spend the evening learning about key innovation taking place at the Midwestern universities and get to know the researchers and entrepreneurs who are driving the efforts.

Midwest University Healthtech Showcase

Central Nervous System

University of Notre Dame The University of Notre Dame has developed novel therapeutics targeting metalloproteinases (MMPs) to minimize disease pathogenesis.
Actualize Therapy (Northwestern) Actualize Therapy has developed a suite of 12 mobile tools that work together to provide computerized therapy for common causes of depression and anxiety, offering a remote way to connect with a therapist in between visits.
Great Lakes Neuroscience Great Lakes Neuroscience is developing TP5, a therepeutic for Primary Progressive Multiple Sclerosis (PPMS) and Amyotrophic Lateral Sclerosis (ALS).
Revivo Therapeutics (University of Illinois–Chicago) Revivo Therapeutics’ newly discovered Nomethiazole therapeutic class offers cognition-enhancing benefits in patients with earlier stage neurodegenerative disease.

Gastrointestinal

University of Louisville Researchers at the University of Louisville is developing next generation gastroenterology surgical devices.
University of Louisville A team of scientists at the University of Louisville have developed a dry-formulated, plant-made cholera toxinn B subunit (CTBp) – a “first-in-class” treatment for Ulcerative Colitis.
ClostraBio (University of Chicago) ClostraBio is dedicated to understanding and treating food allergies. They’ve developed a synthetic prodrug which replicates the function of gut microbiome bacteria to treat life-threatening allergic responses.
Gusto Global (University of Chicago) Gusto Global is a microbiome drug discovery and development company focusing on next generation immune-modulation therapies.

Oncology: Innovative Drug Delivery Systems

Illinois Institute of Technology A team at the Illinois Institute of Technology is developing an antibody drug that conjugates and bifunctional chelating agents for cancer therapy and imaging.
Latona Therapeutics (University of Chicago) Latona Therapeutics has developed a drug-delivery platform based on light-activated drug releasing nanoparticles to selectively target and treat solid tumors.
Iria Pharma (University of Illinois-Urbana Champaign) Iria Pharma is developing the first-ever small molecule-based cancer targeting therapeutics and diagnostics for untreatable cancers.
University of Notre Dame University of Notre Dame researchers are developing PEGylated micellar nanoparticles as efficient cancer drug delivery systems.

Oncology: Immuno-Oncology

Purdue Research Foundation The Purdue Research Foundation is developing a therapeutic for acute myeloid leukemia with a unique target profile.
Northwestern University Northwestern researchers synthesized a high density lipoprotein (HDL)-like nanoparticle (NP) that is useful for the treatment of septic shock, atherosclerosis, and progression of cancer.
NERx Biosciences NERx Biosciences (Indiana University) NERx Biosciences is targeting difficult to treat cancers like lung, ovarian, and pancreatic, that are not effectively treated with existing targeted and immunotherapy using Nucleotide Excision Repair (NER).
Structured Immunity (Notre Dame) Structured Immunity is developing a T-cell receptor optimization for improved cell based immunotherapies.
Neovlv Immunotherapeutics (Washington University) Neovlv Immunotherapeutics has developed a neoantigen-based cancer immunotherapy delivered through outpatient IV infusion that produces stronger, more selective host anti-tumor response that is easily adopted in clinical practice.

Oncology: Tumor Microenvironment and Metastasis Regulation

Northwestern University Northwestern researchers have developed a low molecular weight Ornithine Aminotransferase inhibitor that is useful for the treatment of hepatocellular carcinoma.
Jivana Biotechnology (University of Illinois–Chicago) Jivana kills cancer cells while leaving surrounding health tissues unaffected by down modulating production of a protein found in cancer cells, but not in healthy cells.
Third Coast Therapeutics (Northwestern) Third Coast Therapeutics has developed orally administered small molecule drugs that prevent cancer cell motility that are intended to transform traditional cancer therapies.
University of Notre Dame Notre Dame researchers have two issued patents for their work with ARF6 as a biomarker for tumor invasion and metastasis.

Oncology: Diagnostic and Imaging

University of Louisville Researchers at the University of Louisville have developed computer-aided diagnosis tools for the early, non-invasive detection of lung cancer.
Illinois Institute of Technology Illinois Tech scientists have a prototype of a dual-laser single-beam instrument system (ADEPTTM) enhances resolution in biopsied tumor visualization for cancer detection.
Preora Diagnostics (Northwestern) A Northwestern team has developed a method to detect cancer cells early and away from tumor site by swabbing cells at a peripheral site (e.g. buccal cells for lung cancer) measuring structural disorder of cells at the nanoscale level.
Transnostics LLC (University of Chicago) Transnostics LLC provides a 3D, automated quantitative tissue analysis service for immuno-oncology research.
Ariel Precision Medicine Ariel Precision Medicine’s customized sequencing panels combined with evidence-based precision medicine reports result in early diagnosis, prognosis, and identification of precise treatment options for pancreatic cancer.
Geneoscopy (Washington University) Geneoscopy’s technology diagnoses colorectal cancer noninvasively using human biomarkers in stool samples, replacing the screening colonoscopy.

Renal and Endocrinology

Purdue Research Foundation Researchers at Purdue University have developed a stable form of glucagon that is soluble in aqueous form at neutral pH that can be stored for at least a month at room temperature.
Illinois Institute of Technology A team at the Illinois Institute of Technology has developed a multivariate artificial pancreas system for patients with Type 1 diabetes-adaptive and fault-tolerant control.
Rene Medical (Indiana University) Rene Medical is developing the patent-pending treatment for hospital acquired acute kidney injury.
Simergent Simergent has developed an affordable home dialysis device for emerging markets.

Pain Management

Purdue Research Foundation Researchers at Purdue University have discovered and are developing a non-dependent alternative to opioid painkillers.
University of Louisville Scientists at the University of Louisville have developed a next-generation local anesthetic for eye indications.
Seurat Therapeutics (University of Chicago) Seurat Therapeutics is developing an intranasal migraine medication for high frequency migraine patients.

Other

Innsight Technology, Inc (University of Illinois) Innsight Technology, Inc. has developed a novel point-of-care biosensor of the ocular tear film to improve quality and reduce vision loss.
University of Notre Dame The University of Notre Dame has developed a novel therapeutic that accelerates wound healing and prevents diabetic foot ulcer amputations.
Three Rivers Cardiovascular Systems Three Rivers Cardiovascular Systems has developed SmartGuidewire™ for heart valve replacements and SmartGuidewire™ medical devices to support cardiologists in accurately positioning the new valve during transcatheteraortic valve replacements (TAVR).
Faros Healthcare (Indiana University) Faros Healthcare provides real-time prescriptive analytics that indicate the best patient interventions at the optimal cost using artificial intelligence.
University of Notre Dame Scientists at the University of Notre Dame have discovered novel biomarkers for diagnosing active TB infection.